How to buy BioCryst Pharmaceuticals stock

BioCryst Pharmaceuticals, Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 140 staff and has a trailing 12-month revenue of around USD$49.2 million.

How to buy shares in BioCryst Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for BioCryst Pharmaceuticals. Find the stock by name or ticker symbol: BCRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BioCryst Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of BioCryst Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of BioCryst Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

BioCryst Pharmaceuticals share price

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-10-20.

52-week range	USD$1.38 - USD$6.2862
50-day moving average	USD$3.762
200-day moving average	USD$4.1341
Wall St. target price	USD$8.31
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.154

Buy BioCryst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of BioCryst Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCryst Pharmaceuticals financials

Revenue TTM	USD$49.2 million
Gross profit TTM	USD$-62,334,000
Return on assets TTM	-43.31%
Return on equity TTM	-345.9%
Profit margin	-236.66%
Book value	$0.434
Market capitalisation	USD$619.7 million

TTM: trailing 12 months

Shorting BioCryst Pharmaceuticals shares

There are currently 36.4 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 5% up from 34.6 million last month.

There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.

BioCryst Pharmaceuticals's "short interest ratio" (SIR)

BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 6.1 million). BioCryst Pharmaceuticals's SIR currently stands at 5.94. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 5940 shares are currently held short.

However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 210 shares are currently held short) or 0.2215% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 222 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.

Find out more about how you can short BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $1.38 up to $6.2862. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.6663. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Frequently asked questions

• What percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?

  Currently 0.955% of BioCryst Pharmaceuticals shares are held by insiders and 90.202% by institutions.

• How many people work for BioCryst Pharmaceuticals?

  Latest data suggests 140 work at BioCryst Pharmaceuticals.

• When does the fiscal year end for BioCryst Pharmaceuticals?

  BioCryst Pharmaceuticals's fiscal year ends in December.

• Where is BioCryst Pharmaceuticals based?

  BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703

• What is BioCryst Pharmaceuticals's ISIN number?

  BioCryst Pharmaceuticals's international securities identification number is: US09058V1035

• What is BioCryst Pharmaceuticals's CUSIP number?

  BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103